| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IL-36 beta; IL36B; IL1F8; IL1H2; Interleukin-36 beta; FIL1 eta; Interleukin-1 eta; IL-1 eta; Interleukin-1 family member 8; IL-1F8; Interleukin-1 homolog 2; IL-1H2 |
| Entrez GeneID | 27177 |
| WB Predicted band size | Calculated MW: 19 kDa; Observed MW: 19 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | The antiserum was produced against synthesized peptide derived from the C-terminal region of human IL36B. AA range:111-160 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于IL-36β抗体的3篇参考文献示例(文献信息为虚构示例，仅供格式参考)：
---
1. **文献名称**：*IL-36β signaling drives skin inflammation in psoriasis via neutrophil activation*
**作者**：Tortola L, et al.
**摘要**：研究揭示了IL-36β通过激活中性粒细胞介导银屑病皮肤炎症的机制，并证明靶向IL-36β的抗体可显著减少小鼠模型中的炎症反应。
2. **文献名称**：*Therapeutic targeting of IL-36β in inflammatory bowel disease*
**作者**：Bridgewood C, et al.
**摘要**：该文献报道了一种新型IL-36β中和抗体，在结肠炎模型中通过抑制IL-36β/IL-36R信号通路减轻肠道炎症及组织损伤。
3. **文献名称**：*IL-36β blockade attenuates lung fibrosis in experimental models*
**作者**：Berekmeri A, et al.
**摘要**：研究显示IL-36β抗体通过调节成纤维细胞活化和胶原沉积，有效缓解肺纤维化进展，提示其治疗纤维化疾病的潜力。
---
如需真实文献，建议通过PubMed或Google Scholar搜索关键词“IL-36β antibody”、“IL-36β inhibitor”获取近年研究。
Interleukin-36 beta (IL-36β) is a pro-inflammatory cytokine belonging to the interleukin-1 (IL-1) family, primarily involved in regulating immune and inflammatory responses. It signals through a receptor complex comprising IL-36R (IL-1RL2) and IL-1RAcP, activating downstream pathways like NF-κB and MAPK, which drive the production of inflammatory mediators. IL-36β is highly expressed in epithelial tissues and immune cells, playing a key role in skin inflammation, psoriasis, and autoimmune disorders. Dysregulation of IL-36β is linked to chronic inflammatory diseases, making it a therapeutic target.
IL-36β antibodies are engineered to specifically neutralize IL-36β activity, blocking its interaction with IL-36R and dampening excessive inflammation. These antibodies have shown promise in preclinical and clinical studies for treating conditions like psoriasis, atopic dermatitis, and inflammatory bowel disease. For example, anti-IL-36R antibodies (e.g., spesolimab) have advanced to clinical trials, demonstrating efficacy in generalized pustular psoriasis flares. Targeting IL-36β directly offers a more precise approach compared to broad immunosuppressants, potentially reducing side effects. However, challenges remain in optimizing antibody specificity, delivery, and long-term safety. Research continues to explore IL-36β's role in other diseases, such as fibrosis and arthritis, broadening its therapeutic potential.
×
